WO2022222591A1 - Souche de lactobacillus paracasei pour améliorer l'effet thérapeutique d'un inhibiteur de point de contrôle immunitaire et son utilisation - Google Patents
Souche de lactobacillus paracasei pour améliorer l'effet thérapeutique d'un inhibiteur de point de contrôle immunitaire et son utilisation Download PDFInfo
- Publication number
- WO2022222591A1 WO2022222591A1 PCT/CN2022/077453 CN2022077453W WO2022222591A1 WO 2022222591 A1 WO2022222591 A1 WO 2022222591A1 CN 2022077453 W CN2022077453 W CN 2022077453W WO 2022222591 A1 WO2022222591 A1 WO 2022222591A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- tumor
- strain
- antibody
- paracasei
- therapeutic effect
- Prior art date
Links
- 241000186605 Lactobacillus paracasei Species 0.000 title claims abstract description 30
- 230000001225 therapeutic effect Effects 0.000 title claims abstract description 24
- 229940076838 Immune checkpoint inhibitor Drugs 0.000 title claims abstract description 16
- 108091008026 Inhibitory immune checkpoint proteins Proteins 0.000 title claims abstract description 16
- 102000037984 Inhibitory immune checkpoint proteins Human genes 0.000 title claims abstract description 16
- 239000012274 immune-checkpoint protein inhibitor Substances 0.000 title claims abstract description 16
- 230000002708 enhancing effect Effects 0.000 title claims abstract description 6
- 102100040678 Programmed cell death protein 1 Human genes 0.000 claims abstract 2
- 101710089372 Programmed cell death protein 1 Proteins 0.000 claims abstract 2
- 229940045513 CTLA4 antagonist Drugs 0.000 claims description 5
- 239000003814 drug Substances 0.000 claims description 5
- 238000004321 preservation Methods 0.000 claims description 5
- 102000008096 B7-H1 Antigen Human genes 0.000 claims description 4
- 108010074708 B7-H1 Antigen Proteins 0.000 claims description 4
- 235000013305 food Nutrition 0.000 claims description 4
- 238000002360 preparation method Methods 0.000 claims description 3
- 102000008203 CTLA-4 Antigen Human genes 0.000 claims 1
- 108010021064 CTLA-4 Antigen Proteins 0.000 claims 1
- 210000001744 T-lymphocyte Anatomy 0.000 abstract description 15
- 210000004881 tumor cell Anatomy 0.000 abstract description 7
- 230000008595 infiltration Effects 0.000 abstract description 5
- 238000001764 infiltration Methods 0.000 abstract description 5
- 230000004913 activation Effects 0.000 abstract description 3
- 101100519207 Mus musculus Pdcd1 gene Proteins 0.000 description 49
- 206010028980 Neoplasm Diseases 0.000 description 44
- 241000699670 Mus sp. Species 0.000 description 27
- 230000000968 intestinal effect Effects 0.000 description 25
- 244000005709 gut microbiome Species 0.000 description 22
- 102100034922 T-cell surface glycoprotein CD8 alpha chain Human genes 0.000 description 17
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 14
- 238000011282 treatment Methods 0.000 description 12
- 230000000694 effects Effects 0.000 description 11
- 230000000259 anti-tumor effect Effects 0.000 description 10
- 241000894006 Bacteria Species 0.000 description 9
- 210000001035 gastrointestinal tract Anatomy 0.000 description 8
- 230000001580 bacterial effect Effects 0.000 description 7
- 210000002865 immune cell Anatomy 0.000 description 7
- 230000001965 increasing effect Effects 0.000 description 7
- 235000014655 lactic acid Nutrition 0.000 description 7
- 239000004310 lactic acid Substances 0.000 description 7
- 239000003242 anti bacterial agent Substances 0.000 description 6
- 210000004027 cell Anatomy 0.000 description 5
- 102100039498 Cytotoxic T-lymphocyte protein 4 Human genes 0.000 description 4
- 101000889276 Homo sapiens Cytotoxic T-lymphocyte protein 4 Proteins 0.000 description 4
- 241000186660 Lactobacillus Species 0.000 description 4
- 229940088710 antibiotic agent Drugs 0.000 description 4
- 238000009175 antibody therapy Methods 0.000 description 4
- 230000003115 biocidal effect Effects 0.000 description 4
- 229940039696 lactobacillus Drugs 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- 238000002054 transplantation Methods 0.000 description 4
- 230000004614 tumor growth Effects 0.000 description 4
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 210000001072 colon Anatomy 0.000 description 3
- 230000002596 correlated effect Effects 0.000 description 3
- 238000009169 immunotherapy Methods 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 210000000952 spleen Anatomy 0.000 description 3
- 238000011740 C57BL/6 mouse Methods 0.000 description 2
- 241001608234 Faecalibacterium Species 0.000 description 2
- 102000037982 Immune checkpoint proteins Human genes 0.000 description 2
- 108091008036 Immune checkpoint proteins Proteins 0.000 description 2
- 229930193140 Neomycin Natural products 0.000 description 2
- 108010059993 Vancomycin Proteins 0.000 description 2
- 229960000723 ampicillin Drugs 0.000 description 2
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000005809 anti-tumor immunity Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000000875 corresponding effect Effects 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 239000012636 effector Substances 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 230000002550 fecal effect Effects 0.000 description 2
- 238000003304 gavage Methods 0.000 description 2
- 238000011221 initial treatment Methods 0.000 description 2
- 238000011081 inoculation Methods 0.000 description 2
- 210000004698 lymphocyte Anatomy 0.000 description 2
- 201000001441 melanoma Diseases 0.000 description 2
- 229960000282 metronidazole Drugs 0.000 description 2
- VAOCPAMSLUNLGC-UHFFFAOYSA-N metronidazole Chemical compound CC1=NC=C([N+]([O-])=O)N1CCO VAOCPAMSLUNLGC-UHFFFAOYSA-N 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 229960004927 neomycin Drugs 0.000 description 2
- 238000010899 nucleation Methods 0.000 description 2
- 239000002002 slurry Substances 0.000 description 2
- 229960003165 vancomycin Drugs 0.000 description 2
- MYPYJXKWCTUITO-LYRMYLQWSA-N vancomycin Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C2C=C3C=C1OC1=CC=C(C=C1Cl)[C@@H](O)[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@H]3C(=O)N[C@H]1C(=O)N[C@H](C(N[C@@H](C3=CC(O)=CC(O)=C3C=3C(O)=CC=C1C=3)C(O)=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)O2)=O)NC(=O)[C@@H](CC(C)C)NC)[C@H]1C[C@](C)(N)[C@H](O)[C@H](C)O1 MYPYJXKWCTUITO-LYRMYLQWSA-N 0.000 description 2
- MYPYJXKWCTUITO-UHFFFAOYSA-N vancomycin Natural products O1C(C(=C2)Cl)=CC=C2C(O)C(C(NC(C2=CC(O)=CC(O)=C2C=2C(O)=CC=C3C=2)C(O)=O)=O)NC(=O)C3NC(=O)C2NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(CC(C)C)NC)C(O)C(C=C3Cl)=CC=C3OC3=CC2=CC1=C3OC1OC(CO)C(O)C(O)C1OC1CC(C)(N)C(O)C(C)O1 MYPYJXKWCTUITO-UHFFFAOYSA-N 0.000 description 2
- 238000012070 whole genome sequencing analysis Methods 0.000 description 2
- 241000702462 Akkermansia muciniphila Species 0.000 description 1
- 241000186000 Bifidobacterium Species 0.000 description 1
- 108010008978 Chemokine CXCL10 Proteins 0.000 description 1
- 102000006579 Chemokine CXCL10 Human genes 0.000 description 1
- 241001112695 Clostridiales Species 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 101001057504 Homo sapiens Interferon-stimulated gene 20 kDa protein Proteins 0.000 description 1
- 101001055144 Homo sapiens Interleukin-2 receptor subunit alpha Proteins 0.000 description 1
- 102100037850 Interferon gamma Human genes 0.000 description 1
- 108010074328 Interferon-gamma Proteins 0.000 description 1
- 102100026878 Interleukin-2 receptor subunit alpha Human genes 0.000 description 1
- 244000199866 Lactobacillus casei Species 0.000 description 1
- 235000013958 Lactobacillus casei Nutrition 0.000 description 1
- 206010027480 Metastatic malignant melanoma Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241000736262 Microbiota Species 0.000 description 1
- 210000000662 T-lymphocyte subset Anatomy 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 238000010219 correlation analysis Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 238000000684 flow cytometry Methods 0.000 description 1
- 238000012268 genome sequencing Methods 0.000 description 1
- 210000005008 immunosuppressive cell Anatomy 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 229940017800 lactobacillus casei Drugs 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 231100000225 lethality Toxicity 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 208000021039 metastatic melanoma Diseases 0.000 description 1
- 244000005706 microflora Species 0.000 description 1
- 230000009456 molecular mechanism Effects 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 239000013049 sediment Substances 0.000 description 1
- 239000006152 selective media Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 230000009469 supplementation Effects 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/11—Lactobacillus
- A23V2400/125—Casei
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Genetics & Genomics (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Virology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
La présente invention concerne une souche de Lactobacillus paracasei pour améliorer l'effet thérapeutique d'un inhibiteur de point de contrôle immunitaire et son utilisation, la souche possédant le numéro de dépôt CCTCC NO : M 2020474. En outre, la souche peut recruter et augmenter l'infiltration et l'activation des lymphocytes T CD8 tueurs dans un tissu de cellules tumorales, et promouvoir l'effet thérapeutique d'un anticorps PD-1.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202110434508.2 | 2021-04-22 | ||
CN202110434508.2A CN112877268A (zh) | 2021-04-22 | 2021-04-22 | 一种增强免疫检查点抑制剂治疗效应的干酪乳杆菌株及其应用 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2022222591A1 true WO2022222591A1 (fr) | 2022-10-27 |
Family
ID=76040091
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CN2022/077453 WO2022222591A1 (fr) | 2021-04-22 | 2022-02-23 | Souche de lactobacillus paracasei pour améliorer l'effet thérapeutique d'un inhibiteur de point de contrôle immunitaire et son utilisation |
Country Status (2)
Country | Link |
---|---|
CN (2) | CN112877268A (fr) |
WO (1) | WO2022222591A1 (fr) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN112877268A (zh) * | 2021-04-22 | 2021-06-01 | 上海耀旦生物科技有限公司 | 一种增强免疫检查点抑制剂治疗效应的干酪乳杆菌株及其应用 |
CN114164148B (zh) * | 2021-11-29 | 2022-11-25 | 天津科技大学 | 一株马乳酒样乳杆菌、菌剂及其应用 |
CN114657086A (zh) * | 2021-12-27 | 2022-06-24 | 苏州善佰生物技术有限公司 | 一种双歧杆菌的制备方法及其在肿瘤治疗中的应用 |
CN114306616B (zh) * | 2022-01-12 | 2023-04-28 | 广州知易生物科技有限公司 | 脆弱拟杆菌和免疫检查点抑制剂的新应用 |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2017129769A1 (fr) * | 2016-01-28 | 2017-08-03 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Méthodes permettant d'améliorer la puissance d'inhibiteurs de points de contrôle immunitaires |
WO2018222969A1 (fr) * | 2017-06-02 | 2018-12-06 | Board Of Regents, The University Of Texas System | Espèce bactérienne spécifique et métabolite qui améliore l'efficacité thérapeutique d'un inhibiteur de point de contrôle immunitaire |
CN109771445A (zh) * | 2019-03-20 | 2019-05-21 | 青岛东海药业有限公司 | 酪酸梭菌在制备诱导抗肿瘤免疫及免疫检查点抑制剂增敏制剂中的应用 |
CN109966320A (zh) * | 2019-04-26 | 2019-07-05 | 青岛东海药业有限公司 | 凝结芽孢杆菌在制备诱导抗肿瘤免疫及免疫检查点抑制剂增敏制剂中的应用 |
CN112334141A (zh) * | 2018-06-14 | 2021-02-05 | 株式会社明治 | 用于促进免疫检查点抑制疗法的组合物 |
CN112877268A (zh) * | 2021-04-22 | 2021-06-01 | 上海耀旦生物科技有限公司 | 一种增强免疫检查点抑制剂治疗效应的干酪乳杆菌株及其应用 |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2020500151A (ja) * | 2016-09-27 | 2020-01-09 | ボード オブ リージェンツ, ザ ユニヴァーシティー オブ テキサス システム | マイクロバイオームをモジュレートすることにより、免疫チェックポイント遮断療法を増強するための方法 |
CN110305821B (zh) * | 2019-08-28 | 2019-12-17 | 鲁东大学 | 副干酪乳杆菌配合car-t细胞治疗应用 |
CN111560330B (zh) * | 2020-05-12 | 2022-04-26 | 天津科技大学 | 一种具有免疫调节、抗炎和抗宫颈癌作用的干酪乳杆菌及应用 |
-
2021
- 2021-04-22 CN CN202110434508.2A patent/CN112877268A/zh active Pending
-
2022
- 2022-02-23 CN CN202210169659.4A patent/CN114540229A/zh active Pending
- 2022-02-23 WO PCT/CN2022/077453 patent/WO2022222591A1/fr active Application Filing
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2017129769A1 (fr) * | 2016-01-28 | 2017-08-03 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Méthodes permettant d'améliorer la puissance d'inhibiteurs de points de contrôle immunitaires |
WO2018222969A1 (fr) * | 2017-06-02 | 2018-12-06 | Board Of Regents, The University Of Texas System | Espèce bactérienne spécifique et métabolite qui améliore l'efficacité thérapeutique d'un inhibiteur de point de contrôle immunitaire |
CN112334141A (zh) * | 2018-06-14 | 2021-02-05 | 株式会社明治 | 用于促进免疫检查点抑制疗法的组合物 |
CN109771445A (zh) * | 2019-03-20 | 2019-05-21 | 青岛东海药业有限公司 | 酪酸梭菌在制备诱导抗肿瘤免疫及免疫检查点抑制剂增敏制剂中的应用 |
CN109966320A (zh) * | 2019-04-26 | 2019-07-05 | 青岛东海药业有限公司 | 凝结芽孢杆菌在制备诱导抗肿瘤免疫及免疫检查点抑制剂增敏制剂中的应用 |
CN112877268A (zh) * | 2021-04-22 | 2021-06-01 | 上海耀旦生物科技有限公司 | 一种增强免疫检查点抑制剂治疗效应的干酪乳杆菌株及其应用 |
Non-Patent Citations (3)
Title |
---|
CHEN PING, LIN JIANGUANG, DAI YANGBIN, ZHAO AIYUE, DAI YIJUN, XU TIANWEN: "Progress in understanding the relationship between gut microbiota and immune checkpoint inhibitors ", CHINESE JOURNAL OF CLINICAL ONCOLOGY, TIANJIN SHI YIXUE ZAZHISHE, TIANJIN, CH, vol. 46, no. 24, 30 December 2019 (2019-12-30), CH , pages 1292 - 1296, XP055977952, ISSN: 1000-8179, DOI: 10.3969/j.issn.1000-8179.2019.24.239 * |
JIN YUEPING, DONG HUI, XIA LILIANG, YANG YI, ZHU YONGQIANG, SHEN YAN, ZHENG HUAJUN, YAO CHENGCHENG, WANG YING, LU SHUN: "The Diversity of Gut Microbiome is Associated With Favorable Responses to Anti–Programmed Death 1 Immunotherapy in Chinese Patients With NSCLC", JOURNAL OF THORACIC ONCOLOGY, ELSEVIER INC., US, vol. 14, no. 8, 1 August 2019 (2019-08-01), US , pages 1378 - 1389, XP055809261, ISSN: 1556-0864, DOI: 10.1016/j.jtho.2019.04.007 * |
VYARA MATSON ET AL.: "The commensal microbiome is associated with anti-PD-1 efficacy in metastatic melanoma patients", SCIENCE, vol. 359, no. 6371, 5 January 2018 (2018-01-05), XP055564226, DOI: 10.1126/science.aao3290 * |
Also Published As
Publication number | Publication date |
---|---|
CN112877268A (zh) | 2021-06-01 |
CN114540229A (zh) | 2022-05-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2022222591A1 (fr) | Souche de lactobacillus paracasei pour améliorer l'effet thérapeutique d'un inhibiteur de point de contrôle immunitaire et son utilisation | |
CN110582291A (zh) | 抗pd1/pd-l1/pd-l2抗体的反应性标志物和功效改善用调节剂 | |
CN106170557A (zh) | 作为化疗应答标志物的微生物群组合物,以及微生物调节剂(益生元、益生菌或合生元)用于提高癌症治疗效力的用途 | |
CN109966320B (zh) | 凝结芽孢杆菌在制备诱导抗肿瘤免疫及免疫检查点抑制剂增敏制剂中的应用 | |
CN114452382B (zh) | 脆弱拟杆菌荚膜多糖a与pd-1及pd-l1抗体联合治疗呼吸系统肿瘤的应用 | |
CN116103205B (zh) | 一种粘液玫瑰单胞菌、菌剂和胞外多糖及其制备方法和应用 | |
JP7040701B2 (ja) | 抗がん腫瘍溶解性ウイルス併用療法および優良レスポンダー選択プラットフォーム | |
EP4201416A1 (fr) | Utilisation d'une bactérie dans la préparation d'un synergiste d'inhibiteur de point de contrôle immunitaire | |
CN114404455A (zh) | 脆弱拟杆菌及其两性离子荚膜多糖在制备用于治疗呼吸系统肿瘤药物中的应用 | |
CN109771445B (zh) | 酪酸梭菌在制备诱导抗肿瘤免疫及免疫检查点抑制剂增敏制剂中的应用 | |
CN114344340A (zh) | 脆弱拟杆菌与pd-1及pd-l1抗体联合用药治疗呼吸系统肿瘤中的应用 | |
CN107802659A (zh) | 一种增强免疫功能的静脉注射剂 | |
CN115806893B (zh) | 普通拟杆菌及其组合物在辅助癌症免疫治疗中的应用 | |
Miyaguchi et al. | Treatment with Lactobacillus retards the tumor growth of head and neck squamous cell carcinoma cells inoculated in mice | |
Kim et al. | Supplementation with a high-glucose drink stimulates anti-tumor immune responses to glioblastoma via gut microbiota modulation | |
Halle-Pannenko et al. | Comparison of various BCG preparations in the EORTC—ICIG experimental screening for systemic immunity adjuvants applicable to cancer immunotherapy | |
Hironaka et al. | Essential requirement of toll-like receptor 4 expression on CD11c+ cells for locoregional immunotherapy of malignant ascites using a streptococcal preparation OK-432 | |
RU2658606C1 (ru) | Штамм streptococcus pyogenes n b-7612, продуцент комплекса биологически активных соединений, обладающих иммуностимулирующими свойствами | |
CN116103196B (zh) | 一种活泼瘤胃球菌及其应用 | |
CN117286042A (zh) | 一种增强pd-1单抗治疗效应的罗伊氏乳杆菌株及其应用 | |
CN114164148B (zh) | 一株马乳酒样乳杆菌、菌剂及其应用 | |
CN110090230B (zh) | 凝结芽孢杆菌在制备预防或治疗胆管癌制剂中的应用 | |
CN111991427A (zh) | 肠道细菌在制备用于促进TCR γδ+T细胞增殖的药物中的应用 | |
KR20220169403A (ko) | 락티카제이바실러스 속 또는 락토바실러스 속 균주를 유효성분으로 포함하는 암 진단, 예방 또는 치료용 조성물 | |
Bansal | 1.2 Problems in Identifying Tumor-Specific Sensitized |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 22790701 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 22790701 Country of ref document: EP Kind code of ref document: A1 |